AUG 7, 2026 · PHASE 1 TRIAL
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
ClinicalTrials.gov
Phase 1 dose-escalation trial of a novel bispecific antibody in solid tumors; designed to establish safety and tolerability with preliminary efficacy assessment, not yet recruiting and results not reported.
Reported
Estimated enrollment39
Phase Ia primary outcome: Dose li…Up to 21 days after the first dose
Phase Ia primary outcome: Maximum…Up to 21 days after the first dose